Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation

Kapaettu Satyamoorthy, Gang Li, Michelle R. Gerrero, Marcia S. Brose, Patricia Volpe, Barbara L. Weber, Patricia Van Belle, David E. Elder, Meenhard Herlyn

    Research output: Contribution to journalArticle

    369 Citations (Scopus)

    Abstract

    Dysregulated activation of Ras or its downstream effectors such as mitogen-activated protein kinase kinase and ERK has been shown to play a critical role in tumorigenesis of many cancer types. However, in melanoma, activating mutations in Ras are rarely observed and are limited to N-Ras in UV-exposed cells. In this study, we identify constitutively activated ERK in almost all melanoma cell lines and in tumor tissues tested, which is in contrast to normal melanocytes and several early stage radial growth phase melanoma lines where ERK can be activated by serum or growth factors. Constitutive activation of ERK is preceded by phosphorylation of mitogen-activated protein kinase kinase and c-RAF. In all of the melanoma cell lines tested, Ras is constitutively activated without underlying mutations. On the contrary, activating mutations in the kinase domain of BRAF are present in the majority of the cell lines tested. Furthermore, ERK activation can be partially inhibited from the cell surface using inhibitors of fibroblast growth factor and hepatocyte growth factor but not interleukin 8 signaling pathways. These data suggest that melanoma growth, invasion, and metastasis are attributable to constitutively activated ERK apparently mediated by excessive growth factors through autocrine mechanisms and BRAF kinase activation.

    Original languageEnglish
    Pages (from-to)756-759
    Number of pages4
    JournalCancer Research
    Volume63
    Issue number4
    Publication statusPublished - 15-02-2003

    Fingerprint

    Mitogen-Activated Protein Kinases
    Melanoma
    Intercellular Signaling Peptides and Proteins
    Proto-Oncogene Proteins B-raf
    Mutation
    Mitogen-Activated Protein Kinase Kinases
    Cell Line
    Hepatocyte Growth Factor
    Fibroblast Growth Factors
    Melanocytes
    Growth
    Tumor Cell Line
    Interleukin-8
    Carcinogenesis
    Phosphorylation
    Neoplasm Metastasis
    Serum
    Neoplasms

    All Science Journal Classification (ASJC) codes

    • Cancer Research
    • Oncology

    Cite this

    Satyamoorthy, Kapaettu ; Li, Gang ; Gerrero, Michelle R. ; Brose, Marcia S. ; Volpe, Patricia ; Weber, Barbara L. ; Van Belle, Patricia ; Elder, David E. ; Herlyn, Meenhard. / Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. In: Cancer Research. 2003 ; Vol. 63, No. 4. pp. 756-759.
    @article{5f926215c148454c9df220c212672524,
    title = "Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation",
    abstract = "Dysregulated activation of Ras or its downstream effectors such as mitogen-activated protein kinase kinase and ERK has been shown to play a critical role in tumorigenesis of many cancer types. However, in melanoma, activating mutations in Ras are rarely observed and are limited to N-Ras in UV-exposed cells. In this study, we identify constitutively activated ERK in almost all melanoma cell lines and in tumor tissues tested, which is in contrast to normal melanocytes and several early stage radial growth phase melanoma lines where ERK can be activated by serum or growth factors. Constitutive activation of ERK is preceded by phosphorylation of mitogen-activated protein kinase kinase and c-RAF. In all of the melanoma cell lines tested, Ras is constitutively activated without underlying mutations. On the contrary, activating mutations in the kinase domain of BRAF are present in the majority of the cell lines tested. Furthermore, ERK activation can be partially inhibited from the cell surface using inhibitors of fibroblast growth factor and hepatocyte growth factor but not interleukin 8 signaling pathways. These data suggest that melanoma growth, invasion, and metastasis are attributable to constitutively activated ERK apparently mediated by excessive growth factors through autocrine mechanisms and BRAF kinase activation.",
    author = "Kapaettu Satyamoorthy and Gang Li and Gerrero, {Michelle R.} and Brose, {Marcia S.} and Patricia Volpe and Weber, {Barbara L.} and {Van Belle}, Patricia and Elder, {David E.} and Meenhard Herlyn",
    year = "2003",
    month = "2",
    day = "15",
    language = "English",
    volume = "63",
    pages = "756--759",
    journal = "Journal of Cancer Research",
    issn = "0008-5472",
    publisher = "American Association for Cancer Research Inc.",
    number = "4",

    }

    Satyamoorthy, K, Li, G, Gerrero, MR, Brose, MS, Volpe, P, Weber, BL, Van Belle, P, Elder, DE & Herlyn, M 2003, 'Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation', Cancer Research, vol. 63, no. 4, pp. 756-759.

    Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. / Satyamoorthy, Kapaettu; Li, Gang; Gerrero, Michelle R.; Brose, Marcia S.; Volpe, Patricia; Weber, Barbara L.; Van Belle, Patricia; Elder, David E.; Herlyn, Meenhard.

    In: Cancer Research, Vol. 63, No. 4, 15.02.2003, p. 756-759.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation

    AU - Satyamoorthy, Kapaettu

    AU - Li, Gang

    AU - Gerrero, Michelle R.

    AU - Brose, Marcia S.

    AU - Volpe, Patricia

    AU - Weber, Barbara L.

    AU - Van Belle, Patricia

    AU - Elder, David E.

    AU - Herlyn, Meenhard

    PY - 2003/2/15

    Y1 - 2003/2/15

    N2 - Dysregulated activation of Ras or its downstream effectors such as mitogen-activated protein kinase kinase and ERK has been shown to play a critical role in tumorigenesis of many cancer types. However, in melanoma, activating mutations in Ras are rarely observed and are limited to N-Ras in UV-exposed cells. In this study, we identify constitutively activated ERK in almost all melanoma cell lines and in tumor tissues tested, which is in contrast to normal melanocytes and several early stage radial growth phase melanoma lines where ERK can be activated by serum or growth factors. Constitutive activation of ERK is preceded by phosphorylation of mitogen-activated protein kinase kinase and c-RAF. In all of the melanoma cell lines tested, Ras is constitutively activated without underlying mutations. On the contrary, activating mutations in the kinase domain of BRAF are present in the majority of the cell lines tested. Furthermore, ERK activation can be partially inhibited from the cell surface using inhibitors of fibroblast growth factor and hepatocyte growth factor but not interleukin 8 signaling pathways. These data suggest that melanoma growth, invasion, and metastasis are attributable to constitutively activated ERK apparently mediated by excessive growth factors through autocrine mechanisms and BRAF kinase activation.

    AB - Dysregulated activation of Ras or its downstream effectors such as mitogen-activated protein kinase kinase and ERK has been shown to play a critical role in tumorigenesis of many cancer types. However, in melanoma, activating mutations in Ras are rarely observed and are limited to N-Ras in UV-exposed cells. In this study, we identify constitutively activated ERK in almost all melanoma cell lines and in tumor tissues tested, which is in contrast to normal melanocytes and several early stage radial growth phase melanoma lines where ERK can be activated by serum or growth factors. Constitutive activation of ERK is preceded by phosphorylation of mitogen-activated protein kinase kinase and c-RAF. In all of the melanoma cell lines tested, Ras is constitutively activated without underlying mutations. On the contrary, activating mutations in the kinase domain of BRAF are present in the majority of the cell lines tested. Furthermore, ERK activation can be partially inhibited from the cell surface using inhibitors of fibroblast growth factor and hepatocyte growth factor but not interleukin 8 signaling pathways. These data suggest that melanoma growth, invasion, and metastasis are attributable to constitutively activated ERK apparently mediated by excessive growth factors through autocrine mechanisms and BRAF kinase activation.

    UR - http://www.scopus.com/inward/record.url?scp=0037442752&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0037442752&partnerID=8YFLogxK

    M3 - Article

    VL - 63

    SP - 756

    EP - 759

    JO - Journal of Cancer Research

    JF - Journal of Cancer Research

    SN - 0008-5472

    IS - 4

    ER -